US pharma giant Pfizer (NYSE: PFE) has reported its 2024 first quarter of sales growth since COVID-19 revenue peaked in late 2022.
The company’s quarterly sales grew 3% to $13.3 billion. Adjusted earnings in the quarter totaled $0.60 per share.
Analysts expected earnings of $0.46 per share on $12.96 billion in revenue for the quarter, according to FactSet.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze